Decrease in cellular density of FOXP3+ cells; increase in CD8+ T cell density in tumor adjacent stroma between patients receiving durvalumab and metformin versus durvalumab alone. Greater CD8+ –FOXP3+ intercellular distances associated with pathologic response. This evidence concerns the gene CD8A and neoplasm.